Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACORNASDAQ:ONVONASDAQ:SABSNYSE:SQZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$9.68$0.61▼$24.20$820K1.4119,299 shs416,900 shsONVOOrganovo$3.94$1.56▼$21.96$3.47M1.13617,505 shs243,634 shsSABSSAB Biotherapeutics$1.78-1.7%$1.55$1.00▼$5.01$16.54M0.4765,987 shs47,360 shsSQZSQZ Biotechnologies$0.03$0.03$0.25▼$3.56$826K2.34455,220 shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%0.00%0.00%0.00%ONVOOrganovo0.00%0.00%0.00%-80.00%-82.96%SABSSAB Biotherapeutics-1.66%-3.40%+1.71%+1.71%-34.56%SQZSQZ Biotechnologies0.00%0.00%-30.00%-6.67%+9.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/AN/AN/AN/ASABSSAB Biotherapeutics3.1781 of 5 stars3.53.00.00.03.81.71.3SQZSQZ BiotechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda Therapeutics 0.00N/AN/AN/AONVOOrganovo 0.00N/AN/AN/ASABSSAB Biotherapeutics 3.00Buy$12.20585.39% UpsideSQZSQZ Biotechnologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ACOR, SABS, ONVO, and SQZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025SABSSAB BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/14/2025SABSSAB BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/1/2025SABSSAB BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $20.004/1/2025SABSSAB BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.00N/A0.02($127.17) per share0.00ONVOOrganovo$122K0.00N/AN/A$0.02 per share0.00SABSSAB Biotherapeutics$2.24M7.38N/AN/A$6.21 per share0.29SQZSQZ Biotechnologies$18.16M0.05N/AN/A$1.94 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%N/AONVOOrganovo-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%5/30/2025 (Estimated)SABSSAB Biotherapeutics-$42.19M-$3.70N/AN/AN/A-1,450.14%-94.37%-67.26%8/14/2025 (Estimated)SQZSQZ Biotechnologies-$79.46M-$2.61N/AN/AN/A-369.96%-119.83%-59.90%N/ALatest ACOR, SABS, ONVO, and SQZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025SABSSAB Biotherapeutics-$1.00-$0.56+$0.44-$0.56$0.13 millionN/A3/28/2025Q4 2024SABSSAB Biotherapeutics-$1.16-$1.23-$0.07-$1.23$0.12 million$0.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ASABSSAB BiotherapeuticsN/AN/AN/AN/AN/ASQZSQZ BiotechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26ONVOOrganovoN/A0.721.72SABSSAB Biotherapeutics0.093.693.69SQZSQZ BiotechnologiesN/A3.503.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%ONVOOrganovo8.23%SABSSAB Biotherapeutics7.82%SQZSQZ Biotechnologies38.51%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%ONVOOrganovo3.72%SABSSAB Biotherapeutics26.46%SQZSQZ Biotechnologies16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataONVOOrganovo201.70 million14.79 millionOptionableSABSSAB Biotherapeutics1409.29 million6.79 millionNot OptionableSQZSQZ Biotechnologies1,62029.49 million24.77 millionNot OptionableACOR, SABS, ONVO, and SQZ HeadlinesRecent News About These CompaniesSerica Energy shares drop as Triton suspended until mid-MarchFebruary 18, 2025 | proactiveinvestors.co.ukSerica Energy says 2025 outlook is ‘promising'January 21, 2025 | proactiveinvestors.co.ukSerica Energy expects to remedy “clearly disappointing†recent production performanceJanuary 7, 2025 | proactiveinvestors.co.ukSQZ Biotechnologies Co Ordinary SharesDecember 23, 2024 | morningstar.comPortal Biotechnologies Announces Over 50 Partnerships and Oversubscribed $7M Seed Round Led by IA VenturesDecember 20, 2024 | finance.yahoo.comGlobal Short-Acting Insulin Market is Expected to Cross ~USD 9 Billion by 2030 | DelveInsightSeptember 5, 2024 | prnewswire.co.ukSTEMCELL Launches Novel Cell-Engineering CellPore™ Transfection SystemAugust 1, 2024 | valdostadailytimes.comWhat is the price tag to keep the biotech engine humming in Massachusetts?July 23, 2024 | msn.comSQZ Biotechnologies Company (SQZB)May 22, 2024 | finance.yahoo.comSqz Bio (SQZB) Earnings Dates & ReportsMay 8, 2024 | investing.comVC funding update: who raised money in March?April 1, 2024 | bizjournals.comSQZ, Portal founder Armon Sharei on starting over in biotechMarch 26, 2024 | biopharmadive.comPortal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VCMarch 19, 2024 | finance.yahoo.comSQZ, months after 80% layoffs, opts for liquidation and $11.8M asset fire sale to StemcellMarch 1, 2024 | fiercebiotech.comRx Rundown: Gilead Sciences, Latigo Biotherapeutics, Exscientia and moreFebruary 16, 2024 | mmm-online.comSQZB SQZ Biotechnologies CompanyDecember 28, 2023 | seekingalpha.comSQZ Biotechnologies Co Ordinary Shares SQZBDecember 12, 2023 | morningstar.comSQZ founder Armon Sharei opens Portal to to simplify intracellular deliveryDecember 12, 2023 | fiercebiotech.com'Medicine at a bigger scale': FUJIFILM Diosynth Biotechnologies unveils new Holly Springs drug manufacturing siteNovember 11, 2023 | wral.com‘Difficult but necessary steps’: SQZ lays off 80% of staff, RegenXBio cuts 15%November 9, 2023 | fiercebiotech.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsSuper Micro Computer Stock Clears New Path Higher on Saudi OrdersBy Gabriel Osorio-Mazilli | May 22, 2025View Super Micro Computer Stock Clears New Path Higher on Saudi OrdersT-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip By Jea Yu | April 29, 2025View T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip ACOR, SABS, ONVO, and SQZ Company DescriptionsAcorda Therapeutics NASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Organovo NASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.SAB Biotherapeutics NASDAQ:SABS$1.78 -0.03 (-1.66%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.97 +0.19 (+10.67%) As of 05:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.SQZ Biotechnologies NYSE:SQZ$0.03 0.00 (0.00%) As of 05/23/2025SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
